SalutarisMD is a clinical-stage medical device company that has developed the BetaCurve, a patented device designed to treat various ophthalmic diseases, particularly polypoidal choroidal vasculopathy (PCV) and advanced age-related macular degeneration (wet-AMD). The BetaCurve utilizes precision beta radiotherapy to deliver therapeutic radiation directly to the affected area of the eye, offering a minimally invasive, outpatient procedure that takes only ten minutes and requires just one treatment. This innovative approach aims to provide a promising alternative for patients who do not respond well to traditional anti-VEGF injections, which often require lifelong administration and can lead to inadequate results for many patients.

The technology behind BetaCurve is supported by a robust intellectual property portfolio, including over 73 utility patents and key patents granted in more than 50 countries. The device is FDA 510(k)-cleared and ISO compliant, ensuring its safety and efficacy. By employing a common technique familiar to retina surgeons, the BetaCurve allows for precise targeting of lesions with accurate dosimetry, potentially reducing the treatment burden associated with frequent injections. SalutarisMD's mission is to make this advanced treatment accessible and affordable for all patients, regardless of their economic status or geographic location, thereby aiming to save vision for everyone.

United States

SalutarisMD is a medical device company that specializes in engineering a novel ophthalmic treatment for Wet age-related Macular Degeneration with a minimally invasive procedure.

SalutarisMD

Company Details